The significant reduction in CRP during the CMD phase compared to placebo underscores CMD’s role in alleviating inflammation, making it a promising intervention for managing chronic inflammation in obesity. This evidence concerns the gene CRP and obesity due to melanocortin 4 receptor deficiency.